Works matching AU Hussein, Mohamad

Results: 65
    1
    2
    3
    4
    5

    Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 11, p. 3031, doi. 10.3109/10428194.2015.1023800
    By:
    • Lucas, David M.;
    • Ruppert, Amy S.;
    • Lozanski, Gerard;
    • Dewald, Gordon W.;
    • Lozanski, Arletta;
    • Claus, Rainer;
    • Plass, Christoph;
    • Flinn, Ian W.;
    • Neuberg, Donna S.;
    • Paietta, Elisabeth M.;
    • Bennett, John M.;
    • Jelinek, Diane F.;
    • Gribben, John G.;
    • Hussein, Mohamad A.;
    • Appelbaum, Frederick R.;
    • Larson, Richard A.;
    • Moore, Dennis F.;
    • Tallman, Martin S.;
    • Byrd, John C.;
    • Grever, Michael R.
    Publication type:
    Article
    6
    7
    8
    9
    10

    Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 4, p. 349, doi. 10.1002/ajh.23639
    By:
    • Lazaryan, Aleksandr;
    • Hussein, Mohamad A.;
    • Reu, Frederic J.;
    • Faiman, Beth;
    • Habecker, Becky;
    • Ann Karam, Mary;
    • Reed, Janice;
    • Hamilton, Kimberly;
    • Waksman, Joel;
    • Bruening, Kellie;
    • Srkalovic, Gordan;
    • Andresen, Steven;
    • Kalaycio, Matthew;
    • Sweetenham, John W.;
    • Sobecks, Ronald;
    • Dean, Robert;
    • Knight, Robert;
    • Zeldis, Jerome B.;
    • Baz, Rachid
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19

    The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable.

    Published in:
    European Journal of Haematology, 2003, v. 70, n. 4, p. 263, doi. 10.1034/j.1600-0609.2003.t01-2-00011.x
    By:
    • Anderson, Kenneth C.;
    • Barlogie, Bart;
    • Berenson, James R.;
    • Dalton, William S.;
    • Adams, Julian;
    • Alsina, Melissa;
    • Bekker, Pirow;
    • Bergsagel, Peter L.;
    • Boise, Lawrence;
    • Chan, Kyle;
    • Chanan-Khan, Asher A.;
    • Comenzo, Raymond;
    • Congdon, Deborah;
    • Croucher, Peter;
    • Epstein, Joshua;
    • Fenton, Robert;
    • Fonseca, Rafael;
    • Gallant, Gilles;
    • Hussein, Mohamad A.;
    • Jagannath, Sundar
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27

    Vorinostat in solid and hematologic malignancies.

    Published in:
    Journal of Hematology & Oncology, 2009, v. 2, p. 1, doi. 10.1186/1756-8722-2-31
    By:
    • Siegel, David;
    • Hussein, Mohamad;
    • Belani, Chandra;
    • Robert, Francisco;
    • Galanis, Evanthia;
    • Richon, Victoria M.;
    • Garcia-Vargas, José;
    • Sanz-Rodriguez, Cesar;
    • Rizvi, Syed
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41

    Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma(Performed on behalf of the Zoledronic Acid Breast Cancer and Multiple Myeloma Study Group)

    Published in:
    Cancer (0008543X), 2003, v. 98, n. 8, p. 1735, doi. 10.1002/cncr.11701
    By:
    • Lee S. Rosen;
    • David Gordon;
    • Mary Kaminski;
    • Anthony Howell;
    • Andrew Belch;
    • John Mackey;
    • Justus Apffelstaedt;
    • Mohamad A. Hussein;
    • Robert E. Coleman;
    • Dirk J. Reitsma;
    • Bee-Lian Chen;
    • John J. Seaman
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49
    50